“Just So Grateful.” Artemis II Crew & Eli Lilly’s New GLP-1 Pill 4/30/26

30 Apr 2026 · 43 min · 21 chapters

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Squawk Pod covers two big themes: (1) Eli Lilly’s latest quarter and the global expansion of its GLP-1 weight-loss drugs, including a newly launched oral pill; (2) NASA’s Artemis II crew reflecting on their moon mission, plus brief market/tech headlines (Fed communication, Anthropic valuation, Live Golf funding pullback).

Guests and backgrounds

Eli Lilly CEO David Ricks (pharma executive leading Lilly’s GLP-1/obesity strategy). Artemis II crew: Commander Reid Wiseman (mission commander), Pilot Victor Glover (pilot), Mission Specialist Christina Koch (engineer/scientist; first woman beyond low Earth orbit and first woman to orbit the moon), Mission Specialist Jeremy Hansen (engineer/astronaut).

Key claims

Lilly’s revenue grew 56% YoY; international growth is driven by Europe/China/Brazil launches reaching stride after prior supply constraints. Foundayo oral pill: 20,000+ patients in ~20 days; >1,000/day ramp expected; >80% of initiators are new to the drug class. Artemis II: crew emphasizes “gratitude,” lunar infrastructure potential, and training for rare emergencies.

Notable examples

Artemis II “smoke alarm” training scenario (false alarm); reentry described as 13 min 36 sec focus with parachute stages; food system adapted from ISS.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Chapters

Tap a time to open that second in VO

Eli Lilly's Strong Performance

2:41 to 3:30

Discussion about Eli Lilly's financial growth and international market success.

“Welcome to Squawk Box right here on CNBC.”

Artemis II Crew Insights

3:30 to 6:20

Insights from the Artemis II crew about lunar exploration and infrastructure.

“As you might imagine, Joe, I don't really follow trending things.”

Federal Reserve Drama

6:20 to 7:08

Analysis of the recent Federal Reserve meeting and its implications.

“Caterpillar is up, I think, 40 points to an all-time high based on construction, industrial construction up 38 percent.”

Inflation and Economic Trends

7:08 to 8:29

Discussion on inflation's impact on the economy and potential rate cuts.

“What is the rest of the economy up in terms of that investment?”

Anthropic's Valuation and AI Landscape

8:29 to 10:36

Exploration of Anthropic's funding and the competitive AI environment.

“But I'm just not sure that that was beneficial to the communications process of the Fed to have that every meeting.”

Saudi Arabia's Investment Decisions

10:36 to 14:01

Discussion on Saudi Arabia's withdrawal from Live Golf and broader investment trends.

“This is all being marked to make-believe.”

Golf Investments and Market Shifts

14:01 to 14:55

Discussion on the impact of golf investments and geopolitical shifts on the market.

“created a massive, more than a soap opera, geopolitical one.”

Eli Lilly's Weight Loss Pill Launch

14:55 to 15:16

Overview of Eli Lilly's new weight loss pill and initial market data.

“A new weight loss pill hit the market in April, and CEO David Ricks shares the data so far.”

Eli Lilly's Weight Loss Pill Launch

16:24 to 16:52

Overview of Eli Lilly's new weight loss pill and initial market data.

“Earning cash back on what you buy every day.”

Eli Lilly's Strong Financial Performance

17:01 to 19:11

Discussion on Eli Lilly's revenue growth and market expectations.

“Revenue was increased, was driven by volume growth, but partially offset by lower realized prices for Manjaro and ZepBound.”
Show all 21 chapters

Weight Loss Drug Market Insights

19:11 to 20:55

Insights into the international demand for weight loss drugs and Eli Lilly's strategy.

“You're raising guidance pretty much across the board, but I'm sure that the people that follow your company were already getting a lot more positive on the guidance.”

Launch of FoundEo and Consumer Adoption

20:55 to 22:45

Eli Lilly CEO discusses the launch of FoundEo and its market reception.

“So what can you tell us about the scripts that you've seen so far and how you feel like that pill is stacking up against with the Wagovi pill?”

Future of Weight Loss Medications

22:45 to 25:54

Discussion on the future of weight loss medications and Eli Lilly's innovations.

“Because when you look at a pill like this that's out there now, do you say this has a runway life, a long-term runway life?”

M&A Activity and Corporate Strategy

25:54 to 28:00

Insights into Eli Lilly's mergers and acquisitions strategy for growth.

“quite a spree this year, doing bigger deals and doing more deals than we're used to seeing from you.”

Health Benefits of GLP-1 Pills

28:00 to 29:06

Discover how new medications are significantly impacting chronic diseases and health outcomes.

“Andrew asked about the pill and so forth.”

Insights from the Artemis II Crew

29:06 to 30:09

Learn about the experiences and reflections of the Artemis II astronauts after their mission.

“Next up on Squawk Pod, we're going to space.”

Reflections on Space Travel

31:42 to 36:50

The Artemis II crew shares their emotional and practical experiences from space travel.

“I'm Joe Kernan, along with Andrew Ross Sorkin.”

Living and Working on the Moon

36:50 to 42:00

Discussion on the feasibility of human life and operations on the moon based on recent experiences.

“I think, you know, Reid has mentioned it.”

Parachute Systems and Toilet Troubles

42:00 to 43:11

Exploration of space parachute stages and humorous anecdotes about toilet malfunctions in space.

“Yeah, you have those two stages of parachutes.”

Family Dynamics in Space Travel

43:11 to 44:39

Discussion on the complexities of traveling to space with family and the dynamics involved.

“It's time to let our friends do that, though.”

Building Grit and Curiosity in Children

44:39 to 46:08

Insights on fostering bravery, grit, and curiosity in children through experiences.

“Do you have a sense of whatever you have?”
Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00Introducing the Total Solutions Advantage only from Comcast Business. It's the largest, fastest fiber-powered network for small business. Gig speeds with equipment and security included and a five-year price lock. No one does business like Comcast Business. Switch today. Get started for$60 a month for 12 months when you add an advanced solution to a qualifying internet package. Limited time offer. Restrictions apply. New customers only. Requires 300 megabits per second internet, security edge, and additional qualifying service. One-year agreement, paperless billing, and auto pay with bank account required.

0:29Taxes and fees extra. It's smart to always have a few financial goals and a really smart one you can set. Earning cash back on what you buy every day. And with Discover, you can. Get this. Discover automatically matches all the cash back you've earned at the end of your first year. Seriously, all of it. And we trust you to make smart decisions. After all, you listen to this show. See terms at discover.com slash credit card. Bring in show music, please. This is Squawk Pod and I'm CNBC producer Cameron Costa. On today's episode, Eli Lilly blowing past expectations in its latest quarter, thanks in part to international growth.

1:13Now that Lilly's GLP-1s have been available in Europe, China and Brazil for a few quarters. CEO David Ricks in an exclusive Newsy interview. I think it's answering a question a lot of investors had, which is what's the depth, the breadth of the GOP-1 weight loss consumer market around the world. And here we see just really strong numbers internationally. It turns out people like to lose weight all around the world. Ready, blast off. Artemis II crew has landed on Squawk's set. The groundwork they're laying in space with pilot Victor Glover. Now going that close to the moon and seeing that, hey, There is a place down there that we could have infrastructure to keep us safe.

1:58I think, you know, Reid has mentioned it. If we had a lunar lander, we would go. And so we're a lot closer than it seemed before we launched. And mission specialist Christina Koch on the new frontiers. NASA's job in a lot of ways to open markets. And we're doing that on every frontier that we find. As soon as we opened it in low Earth orbit, we're pushing to the lunar market. Eventually it'll be Mars. But there's nothing theoretically preventing us from doing any of that. Plus Anthropik's eye-popping valuation and a changing of the guard at the Federal Reserve. Steve Leisman is our eye on the Fed.

2:31We have to have a discussion, long, interesting, and probably not trending on the internet about how the Fed is going to change communication under Kevin Worsh. It's Thursday, April 30th, 2026, and SquawkPod begins right now. Stand, Andrew, bye. In three, two, one, cue Andrew. Good morning. Welcome to Squawk Box right here on CNBC. We're live at the Nasdaq market site in Times Square. I'm Andrew Ross Sorkin, along with Joe Kern. Becky is off today.

3:05Anyway, thank you very much, everyone.

3:09I won't see you next time. Real drama at the Fed meeting and news conference yesterday. I'll tell you that sometimes we say that and it's, I don't know, we're kind of fed, you know. I don't know if the entire country is always talking about drama at the Fed, but this might have broken through yesterday. Was it trending anywhere? Not quite trending, but close. As you might imagine, Joe, I don't really follow trending things. It's not really my thing to be trending. But you are certainly a nerdy Fed head. But yes, that is true. For you, it didn't get any better than yesterday. No, it was a good day, but for that purpose.

3:47But I think I'm going to reverse things the way you guys were talking about. You guys put Powell at the lead. And I think the more important thing is the four dissents. OK. Because they're a sign of potential sharp debate to come with the Fed over the direction of rates. That was the drama that this nerd was interested in. The upshot may be it's going to be difficult for the new Fed chair to deliver rate cuts anytime soon. It was the first time since 92 we had four dissents. Three dissenters are regional bank presidents. They opposed the subtle easing bias in the statement. And one governor, Stephen Myron, as he has every time since he joined the Fed, dissented in favor this time of a quarter point cut.

4:21Fed Chair Powell indicated others could join with the dissenters at the next meeting in support of eliminating the easing bias. So absent a sharp decline in unemployment or inflation, it's going to be tougher. The new Fed chair nominee, Kevin Worscht, to engineer a June rate cut or beyond. That assumes he wants one. Here's what's interesting. The dissenters only advocated moving the Fed to where the market is already. After yesterday's strong economic data and another surge in oil prices, futures for December priced just a 10 percent chance of a rate cut, 86 percent chance of no change. That's all the way through December and a 6 percent chance of a hike.

4:56So the market is in the middle, which is where the dissenters want to move the Fed. Meanwhile, on the drama that everybody else is talking about, Treasury Secretary Scott Bessett criticized Powell's decision to stay on the board as a governor, saying it was a violation of all Federal Reserve norms. Powell, early in his press conference, pretty much accused the administration of violating norms as well, saying these legal actions by the administration are unprecedented in our 113-year history. These legal actions by the administration are unprecedented in our 113-year history, and there are ongoing threats of additional such actions.

5:31I worry that these attacks are battering the institution and putting at risk the thing that really matters to the public, which is the ability to conduct monetary policy without taking into consideration political factors. So that's where we are. I don't think, I'm trying to figure out what's most important to our viewers, Joe. You know, what's trending on the internet is not always the case. And I think that the centers and the debate over policy is probably the more important of the two. The news keeps coming, too. And I made the point that, OK, wow, inflation is bad for rate cuts, obviously.

6:09Meanwhile, if you do believe that there's risk to the labor market and to growth because of oil prices, that argues for rate cut. But then so now we've got Caterpillar. Did you see this today? No, I didn't see Caterpillar. Caterpillar is up, I think, 40 points to an all-time high based on construction, industrial construction up 38 percent. I mean, is that where you cut rates? What would it be if you— It is very hard to look around. Power centers, Steve. So AI, power centers, a lot of—I mean, they're not one-offs, but there's ways you can explain it. And maybe the expensing from the big, beautiful bill.

6:47I don't know if I gave you these numbers, Joe, but I ran these numbers yesterday. In the national accounts, information processing equipment year over year up. You want to take a number? Guess, take a guess. Year over year percent change. I don't want to take a guess. 33 percent. This was 38. Okay, now, take out information processing equipment from equipment spending. What is the rest of the economy up in terms of that investment? So it's all that? Or it's three. Okay. So it's all that. That's all coming through. Look, you know, I'm not sure that Kevin wants a cut here. You know, remember he said he said inflation is a choice.

7:25What choice would he make in this? And he said, by the way, he wants this big debate. Let me make another point. It is pretty it has happened many, many times before that Fed officials have dissented because of the guidance. And what did Kevin say? Get rid of the guidance. So I'm not sure this debate would even happen under Kevin Walsh. He wants to get that out of there. Why are you guiding when you don't know where things are? Would he even have a dot plot in this in this context? So we have to have a discussion long, interesting and probably not trending on the Internet about how the Fed is going to change communication under Kevin Warsh.

8:04So many things to think about. No more press conference. I think there'll be a press conference. Personally, if you ask me, I was not in favor of the Fed chair going to the press conference every meeting. He explained yesterday why he did that, and I think it makes sense why he did it, which is that all of a sudden we had lost the ability to move at every meeting if we needed to because the market was sort of attuned to the idea of only when there was a press conference. But I'm just not sure that that was beneficial to the communications process of the Fed to have that every meeting. But it's fine, and they could, and he could roll it back.

8:39I think maybe a press conference when you need it. Right. I think of days of old. There were times when like the Dow kept going up and then you could you could tie it to a takeover of an oil company. And people would say, well, it doesn't really count, but it was happening. It didn't matter what it was. So today it's it's Caterpillar that has the Dow up. The S &P might trade at another. I think one of the things we're trying to understand is one hundred and ten dollar oil. The market hitting new highs. When does that. Right. We keep asking the question, when does that become a real problem for equities?

9:13Talk to Andrew about how much of the economy is moving on silicone and how much is moving on hydro. Wait a minute. Silicone. Unless you're talking about breast implants. Yeah. I'm not trying to show. I'm not doing training. Silicone. Silicone. Silicone. No, silicone is totally different than silicone. Okay. Yeah, there's Silicon Valley and Silicone Valley, which is Beverly Hills. Thank you. Anthropic potential funding milestone for Anthropic. CNBC has learned that the AI company is in talks to raise money at a$900 billion valuation. That would put it ahead of OpenAI's valuation of$852 billion last month.

9:57The source tells CNBC no term sheet has been signed and talks are ongoing. In February, Anthropic was valued at$380 billion. I mean, these are the way they move around, these numbers. The company declining to comment when contacted by CNBC. Do we think that OpenAI, it's constantly going up, obviously. But given the news from a couple of days ago, did at least the rapid increase slow, or did it actually get marked back down a little bit based on users, based on revenue? You're talking about the valuation of OpenAI. Yes, what we just said. We just said OpenAI's valuation was X. I'm sure it was already higher because that was a while ago.

10:40Because nobody's marking this. This is all being marked to make-believe. It seems like you could make up numbers to get to where that. I mean, they're not valued on normal. No. But we're going to talk about this, I imagine, this other anthropic story about this mythos business. I know it just makes me scared. And the idea that the White House is now talking about trying to slow them down further. Just because the technology is too powerful or because of the power. Here's the question. On one side, the argument is the technology is too powerful and that they don't have enough compute power. The argument they are making is they don't have enough compute power.

11:15Yeah. And therefore, the government, which would want to use Mythos 2, wouldn't have enough compute power to actually use it properly, nor would all the companies. And therefore, that actually creates its own danger. That is actually, if that is true and they're worried about that, that is a real problem. And not just a real problem, also is demonstrative of the question mark about whether you need to build more data centers. Because if you don't have the compute power, and then, by the way, certain people have compute power, certain people don't, then the whole dynamic becomes very, very problematic.

11:47Just to know winners and losers and who can actually break into things. That's a wild scenario. If you are cynical and believe that the White House doesn't like Anthropic for political purposes, you would try to slow down Anthropic as much as possible in 100 different ways so that others, maybe Google, maybe OpenAI, could eventually have time to catch up. And there's an argument that that may be going on. Right. Well, if there's not enough, you know, computing power, then we're not going to spend as much money. That's going to slow that down. And all these things that we've counted on to justify these valuations, those will you have to question.

12:32Yes. Those as well. But we have been all along because the numbers anybody can say trillion. Just as easy. It's as easy to say trillion as it is to say billion. But I mean, it makes a difference. Well, a thousand times as much. You know that? I'm not great at math, but I do know that. You know what was good scientific notation? Because it makes everything very clear, right? 10 to the 6th, 10 to the 9th. If you believe that, by the way, you know, we keep talking about the Anthropic Potential IPO and the OpenAI IPO. Then you have to start to mark down and worry about the SpaceX IPO because a portion of that SpaceX market cap is XAI.

13:13Now, people have already marked down some of that because there's real questions about sort of what kind of success they're going to have with that model where it is now. By the way, this Anthropics story could also, the White House Anthropics story, could help XAI. Again, another company that is trying to catch up to where they are. Are you excited about this next story? Yes. You might be. Okay. Saudi Arabia's public investment fund is going to end support for the upstart Live Golf League. This after this year's season is completed. It's according to sources who spoke with CNBC. And they're telling us that a committee of independent directors will evaluate strategic alternatives for the league after Saudi Arabia pulls funding.

13:52Live is expected to lay out details about its future today, including adding new board members and working to secure new long-term financial partners. Live declined to comment and split the world of golf when it founded back in 2021. created a massive, more than a soap opera, geopolitical one. And, of course, you remember, poached some of the top sports players, really upended the PGA in so many ways, and a fascinating situation. But also a note that Saudi and others in the Middle East are pulling back from investments, Joe, in the U.S. I don't know if you saw Matt Bellany's latest newsletter.

14:30He says that there should be some consideration or thought about what's going on with the Paramount deal with Warner Brothers, which might very well include some money from the Middle East. Some money. Petro money, if you will. Cheese will be next. Coming up on Squawk Pod, a big quarter for Eli Lilly and for weight loss drugs. A new weight loss pill hit the market in April, and CEO David Ricks shares the data so far. It's a conversation you will only hear on CNBC. We've been out in the market about 20 days. We've got over 20 ,000 patients using our product at this point. I can tell you today it'll be a lot more than 1 ,000 a day going on.

15:14The product is growing nicely. But just recall, our ramp is going to be a little different because it's a new brand, a new molecule. Does that change our long-term outlook? No.

15:27The world is transforming faster than ever, and standing still isn't an option. At Oppenheimer, we're working at the forefront of the innovation economy to invest where progress begins, finding opportunities that build and protect wealth for individuals and institutions that want a seat at the edge of tomorrow. Put the power of Oppenheimer Thinking to work for you. Wealth Management, Capital Markets, Investment Banking. Your data lives everywhere. On-prem, in the cloud, across apps. Bring it all together with EverPure, the platform that acts like a living system, delivering the latest in data performance, security, and innovation without ever slowing you down.

16:10Sophisticated enough to anticipate your ever-changing data needs, yet simple enough to feel like second nature. Tame your data chaos with EverPure and make storage and data management the simplest part of your business. Visit everpuredata.com to learn more. It's smart to always have a few financial goals. And a really smart one you can set? Earning cash back on what you buy every day. And with Discover, you can. Get this. Discover automatically matches all the cash back you've earned at the end of your first year. Seriously, all of it. And we trust you to make smart decisions. After all, you listen to this show.

16:46See terms at discover.com slash credit card.

16:52This is Squawk Pod from CNBC today with Joe Kernan and Andrew Ross-Organ. Stand by Joe. His mic. Q. Eli Lilly, results topping estimates. Revenue was increased, was driven by volume growth, but partially offset by lower realized prices for Manjaro and ZepBound. And join us now in an exclusive interview. Eli Lilly, CEO David Ricks and our own Angelica Peebles is also with us. It's good to see you, David. And you're moving back closer to a trillion dollar market cap. These numbers, everything is so far above expectations, obviously. But your stock did hit, I think, eleven hundred, almost eleven hundred fifty, I think eleven hundred thirty three dollars at one point.

17:40So, you know, this is all good news. Is it is it? Would it be expected, do you think, because the weight loss market is so hot, but there are pricing pressures? Anything surprising to you? Well, thanks for having me on. Obviously, we had a really strong start to the year, beating expectations. Yes. But, you know, I think impressively, it's like our fifth or sixth quarter in a row posting really strong top line growth numbers here, 56 percent revenue growth year over year. That's not usually something pharmaceutical companies of our size do. And I think it's answering a question a lot of investors had, which is what's the depth, the breadth of the GLP-1 weight loss consumer market around the world?

18:24And here we see just really strong numbers internationally across every geography, strength in the U.S. market across both forums, ZepBound and Manjaro. And the team's executing really well. We're also excited we launched our oral pill just a few weeks ago, off to a strong start there. We're on track with our expectations. And that's the first new brand and new molecule that's launched with obesity in the sort of the modern era. So we're out there building that brand. And so far, the reception and the buzz is very good. And on top of that, Joe, we're investing a lot in the pipeline, our own organic pipeline.

18:59You see the R &D numbers, but also making a few more acquisitions lately to really bolster our long-term growth. So companies in a really good place, and these are, you know, it's a strong start to the year. We're very confident in a good year ahead. You're raising guidance pretty much across the board, but I'm sure that the people that follow your company were already getting a lot more positive on the guidance. Can you just explain for people, how does revenue outside the U.S. increase 81 %? I mean, or volume, 95 % increase in volume of these people just discovering weight loss drugs or something.

19:36How does that happen? To be honest, yes. You may recall, I mean, it seems like a long time ago, maybe to us, but just in late 24, we had pretty much like global supply constraints on these medications. And Lily and our competitor had sort of slowed down global introductions. Here now we're hitting our third or fourth quarter in the major markets across Europe, China, Brazil, populous countries where a lot of this purchasing is consumer. They're paying out of pocket. And I think as those launches have hit stride, you're seeing the breadth and the depth of that consumer market here, which is very strong.

20:14It turns out people like to lose weight all around the world and they're getting the health benefits and seeing real results. We know Terzepatide, Monjaro, and ZepBound is the most effective agent you can use. And we're seeing great adoption really around the world and continued growth in the U.S. I mean, ZepBound's growing something like 70 percent year over year in the quarter. That's incredible to me. And it's a very scaled product. I think Terzepatide in total now annualizing around$50 billion. Morning, Dave. It's Angelica. Thanks for joining us. You know, I have to ask about Fondeo and that launch.

20:49I know it's only been a few weeks, but investors are hanging on to really every scrap of data they can get about those prescriptions. So what can you tell us about the scripts that you've seen so far and how you feel like that pill is stacking up against with the Wagovi pill? Yeah, I'm happy to answer that. I know people are watching this. We're on, you know, this is one of the most closely watched launches I can remember. But just a couple like background things to remember. First of all, it's not analogous to when we launched ZepBound, which was already available in a medicine called Manjaro.

21:17It's the same form. It's not analogous to the Novo product either because they use the same brand name. We have to build a brand and establish a new medicine. You know, doctors aren't going to write medicine they've never heard of. Right. So we have to go out and educate them. It's going to take some time. Access needs to kick in. And of course, we need to build consumer awareness. And we're not yet on TV and advertising our product. So what we're seeing now is basically organic demand, which is pretty strong to us. We've probably in the last, we've been out in the market about 20 days. We've got over 20 ,000 patients using our product at this point.

21:52I can tell you today it'll be a lot more than 1 ,000 a day going on the product. It's growing nicely. But just recall, our ramp is going to be a little different because it's a new brand, a new molecule. Does that change our long-term outlook? No. We're super excited by what we're seeing. And maybe similar to the competitor so far, more than 80 percent of the people who've initiated FoundEo are new, completely new to this category of drugs. So it's it's very expansionary. I think we saw that with a competitor we're seeing with ours in terms of the class opportunity here. And that's very positive from our perspective.

22:27So on track, I'm really pleased with the execution so far. This is going to play out over quarters, not days, Angelica, and just ask people to take a beat and let us execute. I think it's going to be just fine. Hey, David, given how we've we've we've been seeing each other at a couple of different places over the past couple of months, always getting into a discussion about sort of where this all goes. Because when you look at a pill like this that's out there now, do you say this has a runway life, a long-term runway life? Or do you think that things actually are moving so quickly in this space that two, three, four years from now, you're going to have so many more advanced versions of this that the last pill, for example, or some of the drugs in the past won't be able to be effectively amortized over time in the same way?

23:14Well, it's hard to predict, you know, too far into the future. It has been a fast-moving category. And we think of our role, Andrew, is just to keep innovating. But if you think of Foundayo and its role, it's kind of unique because it's very easy to take. It's hard to imagine designing a medicine that would be as easy as just in any time of day, once a day oral pill. We're so used to that routine with other medications we take over-the-counter or prescription. And this will really not be a thing for people to worry about as they go through their day. It's really made for the everyday world. It's also super scalable.

Read the full transcript

23:49And to Joe's earlier question, you know, there are a billion people on the planet who could benefit from these medications. Will we ever reach a billion? I don't know. But right now we're reaching about 20 million. So there's a there's a big runway in front of us. And from a cost and a scalability perspective, using organic chemistry is a lot more efficient than what we have to do, creating auto injectors with peptides, et cetera, which just doesn't seem possible. No, I guess the reason I'm asking the question is people are you know people are already excited about reda for example and whether everyone's going to be on reda and therefore they're not going to be taking this pill that's i guess that's where i'm going with just the innovation so fast yeah choice is good and we're going to offer i mean red is our product right and we hope to introduce that next year by the way you know in a few weeks or a month's time we'll get our first big obesity readout and uh the sign so far is this is going to be really maybe as much as 50 percent better than terzepatide that could be incredible, but that's not for everybody, right?

24:46Not everyone needs to lose that much weight. People on Foundayo lose about 20 to 30 pounds. And when we survey consumers in the U.S. and Europe, actually, that's a lot of what people want to do is lose a bit of weight. Something like terzepatide is closer to 50 pounds. That's Zep bound. And Reda, if you think about it, could be 70 plus. So depending on your situation, you might choose a different option. We've got other options coming too, by the way, two others entered the phase three development in the last six months, a loralintide, which is a highly selective amylin agonist, which promises like GLP-1-like efficacy, but really with very different, much more benign side effect profile.

25:26That's an interesting product for some. And then also brinepetide, which is like a son of terzepatide. We're studying for many new medical uses like brain health and inflammation. So I think this story will continue to play out with different choices. But it's hard to think of something being occupying that place of for the masses, for the everyday routine, something like Foundaio. It really feels like a great fit for that segment. Really quick, I want to talk about M &A because you guys have been on quite a spree this year, doing bigger deals and doing more deals than we're used to seeing from you.

25:59So what else should we expect to see this year? And where do you feel like you still have holes that you need to fill? Well, we said as we were exiting last year, given the outlook for the company, which is getting a lot bigger quickly and producing a lot of cash flow, that we really would prefer to invest that cash flow in future growth. There's a limit to how quickly we can pace out our own organic growth. Probably the best dollar invested in healthcare in the last 10 years has been a dollar we gave to the Lilly Research Lab scientists. It's been incredible performance, but there's a limit to how many we can bring on board and how quickly we can efficiently scale.

26:35So we're going to supplement that with great teams and great assets from outside the company and open the aperture a bit on the kinds of deals we do. You may be surprised to learn in the last couple of years, Lily has done more business development deals than any company in pharma. But we tend to be very focused on early stage small things because those to us can produce the highest ROI. But we're opening up the Aperture to include select assets that are in the clinic that can add to our growth story and have teams around them, maybe a series of assets that can really help us grow in the future, like the Sintessa acquisition, which is modulating sleep and awakeness cycles.

27:11They have multiple assets, a great team there. We think that's a potentially large TAM opportunity and is the kind of thing you should expect to do more of in the coming years. We did like four deals in a month. That was a little unusual for us. So that's just lumpy in terms of how they've come in. But you can expect a continuous cadence of acquisitions like that. And ticking higher as you've been talking, David. Now, 914 bid. It's up about more than$60 this morning for Eli Lilly. We appreciate bringing all that to us and getting testimonials from people that are saying it not for just weight loss, that their health is like.

27:59I mean, that's important. Andrew asked about the pill and so forth. We just read out a study that's pretty interesting that showed we reduced cardiovascular events by 22 percent in people with diabetes, but also reduced all cause death by more than 50 percent. So I think people are really interested in those health benefits. and as well as the weight loss. So, yeah, it's an exciting time for chronic disease. We can really make a big difference here. It is amazing what, you know, even like sleep apnea. I mean, it's bizarre how many things. If you're overweight, it's like all bad things come from that.

28:34It seems like it all goes. Zep bound is indicated for sleep apnea. It's the only new medicine for that. And you wouldn't think of that. And half the people who take it, yeah, half the people who take it have no sleep apnea at the end of the study. It's incredible. Joint pain. We're a 150-year-old company. I have to mention that. We're going to celebrate our birthday next week. And we've never been in a stronger position and in a position to help more people than today. Well, we appreciate you coming on Squawk Box on earnings day most of the time. David, thanks. Yeah, absolutely. Great to be with you guys.

29:04Take care. Next up on Squawk Pod, we're going to space. Well, space explorers are coming to us. The Artemis 2 crew has landed on set. And mission specialist Jeremy Hansen gives us some tips for how to feel like an astronaut here on Earth. I've been really intentional with taking my kids on backpacking trips. And just getting off the grid and getting out there in nature, I think that is one way that people can experience a small part of what we did. We had some incredible views, but it felt a lot like camping. What makes an astronaut extraordinary? Pilot Victor Glover and Commander Reed Wiseman.

29:41Asking questions, but then listening. That has been a game changer for my trajectory. Just be curious about the world, about everything in it. And who's ready to go back? Mission specialist Christina Koch, the first woman to travel beyond low Earth orbit, and the first woman to orbit the moon. So which was it? You ready to go to Mars or you can't wait to get back? It's both. The tension is real. It's time to let our friends do that, though. We're ready to cheerlead for Artemis 3 and Artemis 4. We are taking off right after this.

30:39There's only one Ozempic. Zen pick? I told you it was catchy. This NBA playoffs with FanDuel. You're not just watching the playoffs. You're a part of them. Steve's got the phone, opens FanDuel, and he's going for threes! Be a part of the action on FanDuel. All customers get a profit boost every NBA playoff game day. 21 plus and present in select states. Opt-in required. Bonus issued is not a withdrawal profit boost tokens. Restrictions apply, including any token expiration and max wager amount. See full terms at FanDuel.com slash sportsbook. Gambling problem? Call 1-800-GAMBLER or 1-800-MY-RESET.

31:13It's smart to always have a few financial goals and a really smart one you can set? Earning cash back on what you buy every day. And with Discover, you can. Get this. Discover automatically matches all the cash back you've earned at the end of your first year. Seriously, all of it. And we trust you to make smart decisions. After all, you listen to this show. See terms at discover.com slash credit card.

31:42Welcome back to Squawk Pod. You're watching Squawk Box on CNBC. I'm Joe Kernan, along with Andrew Ross Sorkin. One of the defining stories of the year and one of future generations that may read about it in school is NASA's Artemis II mission. The historic flight was a critical step in NASA's plan to return humans to the moon. Joining us right now, fresh off of a stop at the White House and the moon, is the Artemis II crew at our table, no less, Joe Kernan. Unbelievable. people. Reid Wiseman, Victor Clover, Christina Cook, and Jeremy Hansen, they're all here, and it is awesome. So it's been a couple weeks, but how do you feel now?

32:18I mean, you're sort of on the tour, but how do you feel? Do you go to sleep at night thinking about what it was like being up there at this point still? I do. Yes. Oh, absolutely. I think we've prioritized the last couple weeks being back, being with family, for sure, enjoying Earth, and just processing and internalizing what just happened. What's the biggest internalizing processing part for you? I'd say gratitude. All of the thoughts, the views, the camaraderie at the end of it, the trust the countries and the world had for us to go do the science, but also the poetry and the gratitude. Just so grateful.

32:58I've seen two takes, and I don't know which of you said it. One was that if we were headed for Mars, you guys were ready to go even though it could be six months. It signed me up. I saw someone else said that they couldn't help but think, and this makes me emotional, but looking down at the earth about their family and how distant their family was from them and that feeling, which I get when I fly over to Europe, I think. I look down at the ground and think they're so far away, and I feel the loss. So which was it? You ready to go to Mars or you can't wait to get back? It's both. That tension is real.

33:38It is real. It's real. Because you might be different. You do it, maybe. I'm not sure at this point. I want to go just out of curiosity. I think seeing what you describe as the eclipse of the moon and the sun, no human ever even contemplated seeing that in person. Do you feel close to God when that happens? I will tell you. I mean, everybody's different, I understand, but you must. There were several moments where the only appropriate response was, oh, my God. And it just was in the DNA. That was the only appropriate response for some of the things that we saw. And that was definitely one of those moments.

34:20What did your families think while you were up there before? What were the conversations like the night before? That's what I wanted. The night before launch? The night before launch. The night before launch. Or even maybe months before when you had to say, this is actually happening. We're doing this. One of the most amazing parts of this is the support that we have from our families. And I will tell you, I think the thing that they all took away was no one understands except for them. No one really understands. And the four of us, we also don't understand how it was to be a family member and watch the four of us leave the planet, watch us go around the moon.

34:53We did have email and we got two chances to talk to our families while we were up there. It was very special for us. one morning I woke up about four days into the mission and my daughter had commented on watching the moon rise the night before from college and she thought my dad and his friends are out there and I think that really hit her but we don't even know what they experienced but what we do know is the way they supported the way they showed up for us and we tried to show up for them and each other and each other and if you if you had a limb and I don't know if everyone remembers a limb but if you had a limb attached who would have gone?

35:25Jeremy. You would have gotten All of us. We all would have gone. Absolutely. You all would have gone. The moon was calling you. We were that close. You're looking down at it, and you're just like, all those rock walls. Did you see some potential landing sites? Yeah, all of it. You could pretty much. I wanted to go all over the place. I was like, I'd like to go check that out, and I would like to go check that out. But there was some work to look and actually scout some places. Weren't there? Well, the goal, I mean, there's some really ambitious plans right now for the future Artemis program to get to the south pole of the moon.

35:58We didn't have the best viewing site of the south pole. That's where we're going to go next. But in the future, we were scouting out areas that eventually will probably have identified some things that probably will go be explored because of what we saw. Okay, so can you see people really living on the moon for some period? Now that you've done this and seen this, are you like, okay, I get it. It's totally doable. We can have a whole operation rolling up there. We're going to be using it to put other spaceships from, you know, as a sort of like the JFK. It's going to be a place people will land and then keep going.

36:32We're going to have data centers up there. Does that all speak to you now? One of the reasons that it is easier to see it was an idea that is now more tangible is because we did that with low Earth orbit. We live in low Earth orbit. We live on the International Space Station. And so now going that close to the moon and seeing that, hey, there is a place down there that we could have infrastructure to keep us safe. I think, you know, Reid has mentioned it. If we had a lunar lander, we would go. And so we're a lot closer than it seemed before we launched. Yeah, the time is right. What about being just up there for for long periods of time when people talk about getting to Mars, for example?

37:09Do you say to yourself that's that feels insane or do you think, oh, that seems totally reasonable? And but not just for people going. I'm talking about this en masse, right? Because the conversations we're having at this table among some of the companies like SpaceX and others, this is about potentially thousands, tens of thousands of people doing this eventually. Yeah. You know, NASA's job in a lot of ways is to open markets. And we're doing that on every frontier that we find. As soon as we opened it in low Earth orbit, we're pushing to the lunar market. Eventually it'll be Mars. But there's nothing theoretically preventing us from doing any of that.

37:43And the time is right. Let's also think 100 years ago, if you wanted to go from London to Washington, D.C. or New York, think about what that I mean, you're risking your life to do that. You're probably taking your entire life savings, inventing a craft and doing it. And now we hop on an airplane and we just need to expand. We need to go farther. We need to go past the moon. We need to get to Mars. We need to go beyond Mars. And then you start to pull everything along with you. You slept at different times or slept at different times. Anyone sleep at all? We slept great. We were on one shift. We all slept.

38:14What I'm getting, when a smoke alarm went off? We were awake during that. We had both of them. Who was awake when the smoke, everybody was awake? We were all awake. We were studying. Okay, so you're sitting there. Wow, it's nice out there. A smoke alarm goes off, and what is the initial thought? Straight to our training. Bingo. 100%. I'd have to go straight to the laboratory. Yeah, we study for two primary emergencies. That smoke, fire, and a rapid cabin depress. And we had both of them on our mission. We had enunciations of them, which turned out to not be the case. You thought it was possible for a second?

38:55Absolutely. When that alarm goes off, vigilance. Has the food gotten any better? We didn't find out. What was the smoke? That wasn't really the smoke detector. Okay, both false. That was a real fire alarm. It was the emergency sound. It was the only time in the whole mission we had the full emergency sound. And when the, I'd be done. I'm done. No one for the popcorn. We don't know what it was. The vehicle takes a lot of battery spots, so it shuts down all the power inside and the ventilation down. And now I know what it feels like to be a baked potato inside of an oven. It was pretty interesting.

39:25The interesting thing I think about it, you guys undergo extraordinary amount of training to do this in advance. What would it take for this to work sort of en masse in the future? There are going to have to be people who do basically no training, right? Because some people are going to be going on vacation on the moon, maybe. I don't know. So how would that work, do you think? Honestly, most of our training is for those rare cases of unknown problems happening. So you get a couple of well-trained people. And other than that, it's fairly comfortable. Okay, back to the food. Because everybody always wants to know about the food.

40:01My daughter knew that you guys were coming up. Has the food gotten any better? Fantastic. Food's great. Fantastic. Highly salted, right? You need a lot of salt up there, apparently, to help with the taste. It's challenging because salt would float around the cabin. So we have actually, like, salt water that we can use to season the food. We have garlic paste. The space station has given us a chance to really flush out our food system. And so we took modifications of the food that we have on the space station. And then you get to pick out a few things. And as long as the packaging is safe for space, we can take things that are just at our local grocery store.

40:31Okay. And what does reentry feel like? I mean, when you feel, I mean, when we're watching the speed of it, I'm thinking to myself, look, what does that feel like inside that capsule? First, I want to set it up for you. We were watching the altitude click down six miles a second. About 39 times the speed of sound. Is that the scariest part of this whole situation? Is there a moment? How do you rank the different levels? I wouldn't say scary, but it definitely had my attention for three years. For three years. It was that 13 minutes and 36 seconds was quite a big focus for me for the whole time.

41:07You want some, I mean, we all remember the scary things about reentry with tiles and how hot it gets. I guess you're watching for everything at that point. Listening, feeling, smelling. You feel confident, though, because we've worked so hard on making sure that it can withstand that heat, I guess, coming down. Does it feel warmer? Like, you're very cognizant of that? Like, what's that feel like? Yeah, not right away, but you are looking at a flame right outside the window that in some cases was so bright it was like looking at an arc welder and it was white hot. And then when the parachute hit, and you felt that, right?

41:40Oh, yeah. Glorious. Glorious. Glorious. It's a very violent feeling and you love it. You're so happy for that violent feeling. People need to know about it. They need to warn them about it, you said. Future people need to know. You're going to feel like you're falling off a skyscraper backwards for how long? for 30 seconds? Yeah, you have those two stages of parachutes. These drogues come out, and there's two of them for a bit, but then they release. And between their release and the main, those big red-orange parachutes coming out, you do fall again. Okay, you remember what I said. Bill Paxton, he's great, he's gone now, but the consolation urine, right?

42:18Or urine. But what happened with the toilet? And what did that... How long was it out? Looking at me, did you think I... People break toilets all the time. I've been accused of that before. But it was only for number one, right? That was the only. So the toilet was fine, but the line we used to empty the liquid part of the toilet out was clogging up. And so. What would that mean? We had to create the constellation. Which would create the constellation you're on. But then you fixed that, too, though. Well, we adapted that. Okay. Secondary. There's a primary vent line, and that was clogged. So we couldn't use the urine part of our official toilet.

42:58But we have a secondary vent line, and that never clogged up. So we could use a backup system, which definitely was not as convenient, but it was workable for the length of mission we had. Okay, so who wants to go back? Oh, yeah. Everybody signed up. It's time to let our friends do that, though. We're ready to cheerlead for Artemis 3 and Artemis 4 and see people go back up, do some docking, test out those landers, and eventually walk out of the van. Okay, would you want to go the next time with your families? How do you think everyone would do everybody all together? No, I was thinking about this because you guys all talk about your families.

43:29And I think, oh, maybe everyone should go together. But then I've been in the car ride with all five of us. And sometimes it's complicated. I love it personally. Anyway. I love playing ice fire with my little eyes. We're heading out to the moon with my kids. Back with the alphabet game. If the alphabet game, you wouldn't get very far. Really boring. I think you might be surprised because, you know, the way you show up for one another when you're 250 ,000 miles from Earth, people just stand too. And a lot of grace. You might be surprised by your family. You should try it. It is. I won't go there.

44:03Where are you going to go? We've got a whole crowd. No, I was just going to say, I'm not going to ask you about Iran or anything. I know you've got to ask no questions. We don't need to talk about that. But all we wanted to talk about was your heroism and bravery and everything else and patriotism. And we thank you for that. I always ask, where do we find people like this? Because don't look here. I don't know. Can I go back to that, though? Because this is one thing I was thinking about with kids, actually, which is you guys clearly are brave, courageous. You have something that I wish I had.

44:36It's called the right stuff. And I hope my kids have. And people talk about grit. And how do you sort of create that? Do you have a sense of whatever you have? And do you think that you've figured out a way to bottle it up? for the rest of us? One thing that, you know, I've been really intentional with taking my kids on backpacking trips and just getting off the grid and getting out there in nature and, you know, not having the creature comforts at home. I just, I think that is one way that people can experience a small part of what we did. We had some incredible views, but it felt a lot like camping.

45:08about your childhoods? And look, you know, we joke, we have a hard time, you know, screwing in a light bulb. So I want to know, like, what was going on? You know, I like where you're going. And I think what I want to say, and I'm speaking to especially the young folks, old folks, it applies to us, too. But to the young folks, we didn't show up with the same stuff. We you know that term, the right stuff can make it seem like there's this kind of standard path. It's the paths are very different. The characteristics are very different. And NASA will train you the training to get there, learning to go out and backpack safely.

45:43But you can come from a lot of different places. But there is a path. And I will tell you one thing that I can look back in my past is you mentioned your kids listening, asking questions, but then listening. That has been a game changer for my trajectory. And be curious. Be curious. I think that's the biggest. You see this curiosity in kids. Just be curious about the world, about everything in it. You're always curious. That part we have in spades at this table. Reed, Victor, Christina and Jeremy, thank you on behalf of the American people, on behalf of humanity. Really, it's something. Thank you.

46:14Thank you. Thank you. Thanks for having us. That's Squawk Pod for today. Thank you for listening. Squawk Box is hosted by Joe Kernan, Becky Quick, and Andrew Ross-Sorkin. You can tune in to CNBC every weekday morning at 6 a.m. Eastern to catch them live for three hours. To get the best bits of that broadcast right into your ears, follow Squawk Pod wherever you get your podcasts. We'll meet you right back here tomorrow. Have a great day. We are clear. Thanks, guys.

47:11We'll see you next time.

From the publisher

Home from space, the crew of the Artemis II stops by the Squawk set. Commander Reid Wiseman, Pilot Victor Glover, and Mission Specialists Christina Koch and Jeremy Hansen discuss their brave journey around the moon, the newest frontiers, the emotional and physical toll of takeoff and reentry, and handling snafus–like smoke alarms and toilet troubles–while in space. Eli Lilly CEO David Ricks discusses the drugmaker’s big financial quarter in an exclusive interview. He shares the first prescription numbers of Lilly’s newest GLP-1 pill, Foundayo, as well as how it differs from Zepbound and Novo Nordisk’s Wegovy. Plus, Anthropic is in talks to raise funds at a $900B valuation, the Saudi Public Investment Fund will stop funding the LIV Golf League, and Jerome Powell will remain on the Fed’s Board of Governors after his time as Chairman ends. 

 

Steve Liesman - 3:17

Angelica Peebles & David Ricks - 17:12

Artemis II Crew - 32:06

 

In this episode:

Artemis Crew, @NASAArtemis

Steve Liesman, @steveliesman

Angelica Peebles, @angelicapeebles

Joe Kernen, @JoeSquawk

Andrew Ross Sorkin, @andrewrsorkin

Cameron Costa, @CameronCostaNY


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from Squawk Pod

All 546 episodes
“Just So Grateful.” Artemis II Crew & Eli Lilly’s New GLP-1 Pill 4/30/26Squawk Pod · 43 min
Listen in VO